Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
JACKSONVILLE, Fla., Dec. 4, 2017 /CNW/ -- TapImmune Inc. (NASDAQ:TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that Peter Hoang, President and Chief Executive Officer, will present live at VirtualInvestorConferences.com on December 7, 2017.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register and run the online system check to save time and receive event updates.
Highly vetted technology: Collaborations with Mayo Clinic, AstraZeneca, Memorial Sloan Kettering Cancer Center, U.S. Department of Defense
About TapImmune Inc. TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide- or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells and helper T-cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be given without respect to HLA type. The company's technologies may be used as stand-alone medications or in combination with other treatment modalities.
About VirtualInvestorConferences.com Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE TapImmune Inc.
For further information: TapImmune Inc.: Tiberend Strategic Advisors, Inc., Joshua Drumm, Ph.D. (Investors), (212) 375-2664, [email protected]; David Schemelia (Media), (212) 375-2686, [email protected]; TapImmune Inc.: Aaron Santos, (904) 862-6490, [email protected]; VirtualInvestorConferences.com: John Viglotti, VP, Investor Relations Products and Services, Cision / PR Newswire / MultiVu, Phone 201 360 6767 | Mobile 212 729 8350, [email protected], http://tapimmune.com